Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments

Area of Science:

• Neurology
• Pediatric Medicine
• Immunology

Background:

• Pediatric multiple sclerosis (MS) accounts for 2-5% of cases, characterized by high disease activity and early disability.
• Effective treatment can significantly alter the long-term physical, cognitive, and psychosocial trajectory in young patients.
• Optimizing therapeutic strategies for children and adolescents with MS is a critical clinical imperative.

Purpose of the Study:

• To review current evidence for multiple sclerosis (MS) therapies in pediatric populations.
• To discuss disease-modifying therapies (DMTs), acute relapse management, and symptomatic treatments.
• To explore emerging therapeutic strategies, including remyelination, neuroprotection, and rehabilitation.

Main Methods:

• Review of existing literature on pediatric MS treatment.
• Analysis of randomized controlled trials (RCTs) in youth.
• Examination of approved and investigational therapies for pediatric MS.

Main Results:

• Fingolimod is the first FDA-approved agent for pediatric MS, signifying a new era in treatment.
• Multiple disease-modifying therapies (DMTs) are now available for relapsing MS, including oral, injectable, and infusion options.
• Increased interest in therapies targeting remyelination, neuroprotection, and rehabilitation alongside anti-inflammatory approaches.

Conclusions:

• Optimizing treatment for pediatric MS is essential to mitigate long-term adverse outcomes.
• The approval of fingolimod and ongoing trials are advancing pediatric MS management.
• Further research into emerging therapies is vital for comprehensive pediatric MS care.